MediHelp International launches NESACARD in Romania, aims to sell 5,000 units this year

Georgiana Bendre 28/06/2017 | 15:06

MediHelp International, one of the most important players on the CEE health insurance market, together with Lamp Insurance (UK) and the New Europe Surgical Academy (Germany) have launched the NESACARD in Romania.

This  is a solution for financing the first stages of investigations, medical navigation and second opinion in case of unexpected cancer diagnostics while, at the same time, it is a charitable contribution to the advancement in oncological treatment and research in Europe.

It can be obtained by filling in an underwriting stating that the insured persons haven’t suffered from any oncological problem and then pay a EUR 33 yearly contribution. MediHelp will also collaborate with brokers and banks to promote NESACARD.

This new system will pay EUR 2,000 in cash, to help with first stages oncological investigations and diagnostics for insured patients.

“Each year, out of 80,000 patients diagnosed with cancer in Romania, 30,000 people die, according to official sources. At the same time, according representatives of the National Society of Medical Oncology in Romania, the number of oncologists – around 250-300 in Romania – is insufficient to take care of all the cases. The partnership with NESA and Lamp is another proof of our commitment to health made available. We hope to sell 5,000 units of NESACARD until the end of the year, but we’ll see,” says Zahal Levy, president of MediHelp International (photo).

“We are here to help, in case patients will need, with the relevant treatment and the right choice of medical providers,” says Prof. Dr. Michael Stark, president of NESA.

Founded in 2004 and based in Berlin, NESA is recognized as one of the most important international surgical networks which includes pan-European and global opinion leaders in oncology and in oncological surgery.

Close ×

We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

Accept & continue